Tumor-specific T-cell immunity: ready for prime time?
作者信息
Greenberg P D, Riddell S R
出版信息
J Natl Cancer Inst. 1992 Jul 15;84(14):1059-61. doi: 10.1093/jnci/84.14.1059.
PMID:1619675
Abstract
摘要
相似文献
1
Tumor-specific T-cell immunity: ready for prime time?
J Natl Cancer Inst. 1992 Jul 15;84(14):1059-61. doi: 10.1093/jnci/84.14.1059.
2
Escape mechanisms in tumor immunity: an update.肿瘤免疫逃逸机制：最新进展
J Environ Pathol Toxicol Oncol. 2002;21(4):277-330.
3
Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?新抗原异质性：免疫反应及对免疫检查点阻断敏感性的关键驱动因素？
Immunotherapy. 2016 Jun;8(7):763-6. doi: 10.2217/imt-2016-0064.
4
Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers.HNPCC患者和健康的HNPCC突变携带者针对移码诱导新肽的免疫反应。
Gastroenterology. 2008 Aug;135(2):711-2; author reply 712-3. doi: 10.1053/j.gastro.2008.04.040. Epub 2008 Jul 9.
5
Targeting tumours with genetically enhanced T lymphocytes.利用基因增强的T淋巴细胞靶向肿瘤。
Nat Rev Cancer. 2003 Jan;3(1):35-45. doi: 10.1038/nrc971.
6
Recognition of tumor-associated antigens by T lymphocytes: from basic concepts to new approaches.T淋巴细胞对肿瘤相关抗原的识别：从基本概念到新方法
Ann Oncol. 1992 Jan;3(1):11-6. doi: 10.1093/oxfordjournals.annonc.a058055.
7
Cancer immunotherapy: a treatment for the masses.癌症免疫疗法：一种面向大众的治疗方法。
Science. 2004 Jul 9;305(5681):200-5. doi: 10.1126/science.1100369.
8
CAR T Cell Therapy for Solid Tumors.嵌合抗原受体 T 细胞疗法治疗实体瘤。
Annu Rev Med. 2017 Jan 14;68:139-152. doi: 10.1146/annurev-med-062315-120245. Epub 2016 Nov 17.
9
The Antigenicity of the Tumor Cell - Context Matters.肿瘤细胞的抗原性——背景很重要。
N Engl J Med. 2017 Feb 2;376(5):491-493. doi: 10.1056/NEJMcibr1613793.
10
Zotero 插件